Dr. Gradishar on Selecting Agents for HER2+ Breast Cancer

William J. Gradishar, MD
Published: Friday, Aug 18, 2017



William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

HER2 breast cancer has seen the introduction of several new agents over the last decade.

One of the challenges, particularly in patients with metastatic disease, is how to optimally use these drugs to deliever the best benefit to the patient, says Gradishar.
 


William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

HER2 breast cancer has seen the introduction of several new agents over the last decade.

One of the challenges, particularly in patients with metastatic disease, is how to optimally use these drugs to deliever the best benefit to the patient, says Gradishar.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x